Intra-Cellular Therapies EPS - Earnings per Share 2013-2022 | ITCI

Intra-Cellular Therapies annual and quarterly earnings per share history from 2013 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Intra-Cellular Therapies EPS for the quarter ending March 31, 2022 was $-0.78, a 20% increase year-over-year.
  • Intra-Cellular Therapies EPS for the twelve months ending March 31, 2022 was $-3.63, a 15.24% increase year-over-year.
  • Intra-Cellular Therapies 2021 annual EPS was $-3.5, a 8.36% increase from 2020.
  • Intra-Cellular Therapies 2020 annual EPS was $-3.23, a 20.52% increase from 2019.
  • Intra-Cellular Therapies 2019 annual EPS was $-2.68, a 5.63% decline from 2018.
Intra-Cellular Therapies Annual EPS
2021 $-3.50
2020 $-3.23
2019 $-2.68
2018 $-2.84
2017 $-2.12
2016 $-2.69
2015 $-2.91
2014 $-1.07
2013 $-1.56
2012 $-2.96
Intra-Cellular Therapies Quarterly EPS
2022-03-31 $-0.78
2021-12-31 $-1.05
2021-09-30 $-0.95
2021-06-30 $-0.85
2021-03-31 $-0.65
2020-12-31 $-0.75
2020-09-30 $-0.79
2020-06-30 $-0.96
2020-03-31 $-0.73
2019-12-31 $-0.74
2019-09-30 $-0.63
2019-06-30 $-0.68
2019-03-31 $-0.63
2018-12-31 $-0.75
2018-09-30 $-0.76
2018-06-30 $-0.68
2018-03-31 $-0.65
2017-12-31 $-0.56
2017-09-30 $-0.53
2017-06-30 $-0.41
2017-03-31 $-0.62
2016-12-31 $-0.64
2016-09-30 $-0.70
2016-06-30 $-0.71
2016-03-31 $-0.64
2015-12-31 $-0.67
2015-09-30 $-0.91
2015-06-30 $-0.61
2015-03-31 $-0.72
2014-12-31 $-0.53
2014-09-30 $-0.22
2014-06-30 $-0.15
2014-03-31 $-0.17
2013-12-31 $-0.33
2013-09-30 $-0.28
2013-06-30 $-0.56
2013-03-31 $-0.39
2012-12-31 $0.00
2012-09-30 $-0.40
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.539B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00